GPP
Great Point Partners Portfolio holdings
AUM
$154M
1-Year Return
2.36%
This Quarter Return
-1.38%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$506M
AUM Growth
+$22.3M
(+4.6%)
Cap. Flow
+$30.4M
Cap. Flow
% of AUM
6%
Top 10 Holdings %
Top 10 Hldgs %
51.22%
Holding
56
New
14
Increased
12
Reduced
14
Closed
12
Top Buys
| 1 |
Cytokinetics
CYTK
|
$17.6M |
| 2 |
Amylyx Pharmaceuticals
AMLX
|
$17.4M |
| 3 |
AnaptysBio
ANAB
|
$17.2M |
| 4 |
Evolus
EOLS
|
$16.9M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
$13.4M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$20.6M |
| 2 |
Ventyx Biosciences
VTYX
|
$13.1M |
| 3 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
$12.5M |
| 4 |
PTC Therapeutics
PTCT
|
$11.5M |
| 5 |
Sarepta Therapeutics
SRPT
|
$9.46M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
MoonLake Immunotherapeutics
MLTX
$3.85B
| $5.95M | 1.17% |
278,334
-364,232
| -57% | -$7.79M |
|
|
GRCL
27
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $5.86M | 1.15% |
3,153,206
+1,190,807
| +61% | +$2.21M |
|
|
CBAY
28
DELISTED
Cymabay Therapeutics
CBAY
| $4.43M | 0.87% |
507,500
-1,042,500
| -67% | -$9.09M |
|
29
Generation Bio
GBIO
$40M
| $4.4M | 0.86% |
102,254
| – | – |
|
30
Acumen Pharmaceuticals
ABOS
$86.6M
| $4.27M | 0.84% |
1,051,267
-65,314
| -6% | -$265K |
|
31
Amicus Therapeutics
FOLD
$2.51B
| $4.21M | 0.83% |
+380,000
| New | +$4.21M |
|
32
Larimar Therapeutics
LRMR
$342M
| $4.08M | 0.8% |
900,000
-373,635
| -29% | -$1.69M |
|
|
ITCI
33
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $3.81M | 0.75% |
+70,371
| New | +$3.81M |
|
34
89bio
ETNB
$1.3B
| $3.81M | 0.75% |
+250,000
| New | +$3.81M |
|
35
Zevra Therapeutics
ZVRA
$500M
| $1.91M | 0.38% |
+347,824
| New | +$1.91M |
|
36
Day One Biopharmaceuticals
DAWN
$771M
| $1.89M | 0.37% |
141,526
-402,925
| -74% | -$5.39M |
|
37
Rhythm Pharmaceuticals
RYTM
$6.83B
| $1.74M | 0.34% |
+97,544
| New | +$1.74M |
|
38
Praxis Precision Medicines
PRAX
$971M
| $1.64M | 0.32% |
+135,503
| New | +$1.64M |
|
39
Solid Biosciences
SLDB
$425M
| $997K | 0.2% |
+210,405
| New | +$997K |
|
40
Avalo Therapeutics
AVTX
$156M
| $831K | 0.16% |
+1,978
| New | +$831K |
|
|
OKUR
41
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$35.7M
| $723K | 0.14% |
+12,086
| New | +$723K |
|
42
UroGen Pharma
URGN
$882M
| $362K | 0.07% |
39,222
-520,778
| -93% | -$4.81M |
|
43
Immunic
IMUX
$74.3M
| – | – |
-632,184
| Closed | -$885K |
|
44
NovoCure
NVCR
$1.36B
| – | – |
0
| – | – |
|
|
45
PTC Therapeutics
PTCT
$4.59B
| – | – |
-302,135
| Closed | -$11.5M |
|
46
Alkermes
ALKS
$4.96B
| – | – |
-46,185
| Closed | -$1.21M |
|
47
Erasca
ERAS
$440M
| – | – |
-1,538,461
| Closed | -$6.63M |
|
48
Rocket Pharmaceuticals
RCKT
$353M
| – | – |
0
| – | – |
|
|
49
Sarepta Therapeutics
SRPT
$1.93B
| – | – |
-73,000
| Closed | -$9.46M |
|
|
VERV
50
DELISTED
Verve Therapeutics
VERV
| – | – |
-300,000
| Closed | -$5.81M |
|